PMID- 15694016
OWN - NLM
STAT- MEDLINE
DCOM- 20050531
LR  - 20181201
IS  - 1525-7304 (Print)
IS  - 1525-7304 (Linking)
VI  - 6
IP  - 4
DP  - 2005 Jan
TI  - Nonclassical retinoids and lung carcinogenesis.
PG  - 237-44
AB  - The retinoids are natural and synthetic derivatives of vitamin A. These cancer 
      therapeutic and chemopreventive agents exert antiproliferative, 
      differentiation-inducing, proapoptotic, and other biologic effects. The retinoids 
      act through nuclear retinoid receptors to activate target genes that signal 
      biologic effects. Agents that specifically activate the nuclear retinoid X 
      receptors (RXRs) are known as rexinoids. Rexinoid growth suppression of human 
      bronchial epithelial cells was linked to triggering of G1 cell cycle arrest, 
      concomitant growth suppression, and a decrease in expression of G1 cyclins 
      through activation of a proteasome-dependent degradation pathway. Clinical 
      studies have demonstrated prolonged survival of subsets of patients with 
      non-small-cell lung cancer (NSCLC) treated with rexinoids as single agents or as 
      part of combination regimens. The critical role of RXR in downstream signaling 
      makes rexinoids especially attractive agents to consider in combination therapy. 
      There is encouraging evidence for therapeutic benefit of combination regimens of 
      rexinoids with other targeted agents, such as epidermal growth factor receptor 
      inhibitors, and with chemotherapy. Results from randomized phase III clinical 
      trials in NSCLC will ultimately determine the impact for rexinoid-based therapy 
      or chemoprevention for lung cancer.
FAU - Dragnev, Konstantin H
AU  - Dragnev KH
AD  - Hematology/Oncology Section, Department of Medicine, Dartmouth-Hitchcock Medical 
      Center, Hanover, NH 03756, USA. dragnev@dartmouth.edu
FAU - Petty, W Jeffrey
AU  - Petty WJ
FAU - Ma, Yan
AU  - Ma Y
FAU - Rigas, James R
AU  - Rigas JR
FAU - Dmitrovsky, Ethan
AU  - Dmitrovsky E
LA  - eng
GR  - R01CA 87546/CA/NCI NIH HHS/United States
GR  - T32-CA09658/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Clin Lung Cancer
JT  - Clinical lung cancer
JID - 100893225
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Cyclins)
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (Retinoids)
RN  - 0 (Tetrahydronaphthalenes)
RN  - 0 (Ubiquitin)
RN  - A61RXM4375 (Bexarotene)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
SB  - IM
MH  - Anticarcinogenic Agents/pharmacology/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bexarotene
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism
MH  - Cyclins/metabolism
MH  - ErbB Receptors/antagonists & inhibitors
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/metabolism
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Receptors, Retinoic Acid/agonists
MH  - Retinoids/metabolism/pharmacology
MH  - Tetrahydronaphthalenes/pharmacology/*therapeutic use
MH  - Ubiquitin/metabolism
RF  - 95
EDAT- 2005/02/08 09:00
MHDA- 2005/06/01 09:00
CRDT- 2005/02/08 09:00
PHST- 2005/02/08 09:00 [pubmed]
PHST- 2005/06/01 09:00 [medline]
PHST- 2005/02/08 09:00 [entrez]
AID - S1525-7304(11)70475-2 [pii]
AID - 10.3816/CLC.2005.n.003 [doi]
PST - ppublish
SO  - Clin Lung Cancer. 2005 Jan;6(4):237-44. doi: 10.3816/CLC.2005.n.003.